Amoy Diagnostics Co

Amoy Diagnostics Co R&D per Employee

The R&D Spending per Employee of Amoy Diagnostics Co (300685.SZ) as of Nov 12, 2026 is 161,296.43 CNY. In the previous year, R&D Spending per Employee was 196,289.04 CNY — a change of -17.83% (lower).

R&D per Employee

161,296.43CNY

YoY

-17.83%

Last updated:

R&D Spending per Employee of Amoy Diagnostics Co is 2025 161,296.43 CNY. R&D Spending per Employee of Amoy Diagnostics Co was 2024 196,289.04 CNY. It decreases by -17.83% lower compared to the previous year.

The Amoy Diagnostics Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
71,150.13 CNY
Jan 1, 2019
85,153.67 CNY
Jan 1, 2020
104,546.07 CNY
Jan 1, 2021
115,285.63 CNY
Jan 1, 2022
158,521.24 CNY
Jan 1, 2023
184,575.20 CNY
Jan 1, 2024
196,289.04 CNY
Jan 1, 2025
161,296.43 CNY
The Amoy Diagnostics Co R&D per Employee history
YEARR&D per EmployeeYoY
161,296.43CNY-17.83%
196,289.04CNY+6.35%
184,575.20CNY+16.44%
158,521.24CNY+37.50%
115,285.63CNY+10.27%
104,546.07CNY+22.77%
85,153.67CNY+19.68%
71,150.13CNY+54.12%
46,165.43CNY+3.07%
44,789.38CNY+45.99%
30,678.86CNY+65.60%
18,525.42CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amoy Diagnostics Co Stock analysis

What does Amoy Diagnostics Co do? Amoy Diagnostics Co., Ltd. generates revenue through the sale of tumor precision molecular diagnostic products, including ADx-ARMS, Super-ARMS, NGS, and FISH testing reagents. These reagents are used for detecting non-small cell lung cancer, colorectal cancer, thyroid cancer, and melanoma in tumor tissue specimens and liquid biopsies. The company also offers data software for gene sequencing data analysis and provides testing services via its medical testing institutions for lung cancer, colorectal cancer, and breast cancer. Revenue streams include reagent sales, software licensing, and diagnostic testing services. The primary customers are medical institutions and healthcare providers requiring tumor molecular diagnostics. The ADx-ARMS product line targets tumor tissue specimen detection, while Super-ARMS serves liquid biopsy applications. NGS and FISH products support comprehensive tumor genetic analysis. Testing services focus on lung, colorectal, and breast cancer diagnostics, catering to hospitals and clinics specializing in oncology. The company’s offerings align with the demand for precise cancer diagnosis and treatment planning. Amoy Diagnostics’ revenue model combines product sales with service-based offerings. Reagent products like ADx-ARMS and Super-ARMS are sold to medical facilities for routine tumor testing. Data software for gene sequencing analysis is licensed to research institutions and hospitals. Testing services through its medical testing institutions provide direct diagnostic solutions for specific cancers, enhancing customer retention through integrated service packages. Amoy Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amoy Diagnostics Co stock

R&D Spending per Employee of Amoy Diagnostics Co is 161,296.43 CNY in 2025.

R&D Spending per Employee of Amoy Diagnostics Co changed from 196,289.04 CNY to 161,296.43 CNY, representing a -17.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Amoy Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Amoy Diagnostics Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Amoy Diagnostics Co

All Key Metrics — Amoy Diagnostics Co